Hadronic Contributions to the Muon Anomaly in the Constituent Chiral Quark Model

The hadronic contributions to the anomalous magnetic moment of the muon which are relevant for the confrontation between theory and experiment at the present level of accuracy, are evaluated within the same framework: the constituent chiral quark model. This includes the contributions from the dominant hadronic vacuum polarization as well as from the next--to--leading order hadronic vacuum polarization, the contributions from the hadronic light-by-light scattering, and the contributions from the electroweak hadronic $Z\gamma\gamma$ vertex. They are all evaluated as a function of only one free parameter: the constituent quark mass. We also comment on the comparison between our results and other phenomenological evaluations.Comment: Several misprints corrected and a clarifying sentence added. Three figures superposed and two references added. Version to appear in JHE

Hadronic light-by-light corrections to the muon g-2: the pion-pole contribution

The correction to the muon anomalous magnetic moment from the pion-pole contribution to the hadronic light-by-light scattering is considered using a description of the pi0 - gamma* - gamma* transition form factor based on the large-Nc and short-distance properties of QCD. The resulting two-loop integrals are treated by first performing the angular integration analytically, using the method of Gegenbauer polynomials, followed by a numerical evaluation of the remaining two-dimensional integration over the moduli of the Euclidean loop momenta. The value obtained, a_{mu}(LbyL;pi0) = +5.8 (1.0) x 10^{-10}, disagrees with other recent calculations. In the case of the vector meson dominance form factor, the result obtained by following the same procedure reads a_{mu}(LbyL;pi0)_{VMD} = +5.6 x 10^{-10}, and differs only by its overall sign from the value obtained by previous authors. Inclusion of the eta and eta-prime poles gives a total value a_{mu}(LbyL;PS) = +8.3 (1.2) x 10^{-10} for the three pseudoscalar states. This result substantially reduces the difference between the experimental value of a_{mu} and its theoretical counterpart in the standard model.Comment: 27 pages, Latex, 3 figures. v2: version to be published in Phys. Rev. D, Note added and references updated (don't worry, sign has not changed

The Muon Anomalous Magnetic Moment: A Harbinger For "New Physics"

QED, Hadronic, and Electroweak Standard Model contributions to the muon anomalous magnetic moment, a_mu = (g_mu-2)/2, and their theoretical uncertainties are scrutinized. The status and implications of the recently reported 2.6 sigma experiment vs.theory deviation a_mu^{exp}-a_mu^{SM} = 426(165) times 10^{-11} are discussed. Possible explanations due to supersymmetric loop effects with m_{SUSY} \simeq 55 sqrt{tan beta} GeV, radiative mass mechanisms at the 1--2 TeV scale and other ``New Physics'' scenarios are examined.Comment: 24 page

The renormalization group inspired approaches and estimates of the tenth-order corrections to the muon anomaly in QED

We present the estimates of the five-loop QED corrections to the muon anomaly using the scheme-invariant approaches and demonstrate that they are in good agreement with the results of exact calculations of the corresponding tenth-order diagrams supplemented by the additional guess about the values of the non-calculated contributions.Comment: LATEX 15 pages, figures available upon request; preprint CERN-TH.7518/9

Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART

The identification of clinical risk factors for AIDS in patients with preserved immune function is of significant interest. We examined whether patients with fungal infection (FI) and CD4 cell count >/=200/microl were at higher risk of disease progression in the era of cART. 11,009 EuroSIDA patients were followed from their first CD4 cell count >/=200/microl after 1 January 1997 until progression to any non-azoles/amphotericin B susceptible (AAS) AIDS disease, last visit or death. Initiation of antimycotic therapy (AMT) was used as a marker of FI and was modelled as a time-updated covariate using Poisson regression. After adjustment for current CD4 cell count, HIV-RNA, starting cART and diagnosis of AAS-AIDS, AMT was significantly associated with an increased incidence of non-AAS-AIDS (IRR=1.55, 95% CI 1.17-2.06, p=0.0024). Despite low incidence of AIDS in the cART era, FI in patients with a CD4 cell count >/=200/microl is associated with a 55% higher risk of non-AAS-AIDS (95% confidence interval 1.17-2.06, p=0.0024). These data suggest that patients with FI are more immune compromized than would be expected from their CD4 cell count alone. FI can be used as a clinical marker for disease progression and indirect indicator for initiation/changing cART in settings where laboratory facilities are limited

Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999

Regional differences across Europe in triple class failure (TCF; the failure of each of the three separate main classes of antiretrovirals (ARVs) with a viral load >1000 HIV-1 RNA copies/mL for >4 months) have not been described. A total of 1956 patients started combination ARV therapy after 1 January 1999, of whom 123 patients developed TCF [6.3%; incidence 16.7 per 1000 person-years of follow-up; 95% confidence interval (CI) 13.7\u201319.6]. After adjustment, patients from Eastern Europe had a significantly increased incidence of TCF compared with patients from Southern Europe/Argentina (3.05; 95% CI 1.36\u20136.82; P=0.0067) while patients taking either a boosted protease inhibitor regimen (0.33; 95% CI 0.15\u20130.74; P=0.0072) or a nonnucleotide reverse transcriptase inhibitor (NNRTI)-based regimen (0.59; 95% CI 0.37\u20130.94; P=0.026) had a reduced incidence of TC